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To the Editor:
WHIM (warts-hypogammaglobulinemia-infections-myelokathexis) syndrome is an autosomal 
dominant primary immunodeficiency disorder caused by mutation of the CXC chemokine 
receptor 4 (CXCR4) gene (1, 2). Affected patients suffer from recurrent infections of the 
respiratory tract and soft tissues, and marked susceptibility to warts caused by human 
papilloma viruses from the second decade of life (3, 4). Granulocyte-macrophage colony 
stimulating factor (G-CSF) has been used to increase and maintain an adequate number of 
circulating neutrophils, and administration of intravenous immunoglobulin (IVIG) 
concentrates may help to decrease the number of infectious episodes caused by extracellular 
pathogens (5, 6). Nevertheless, the optimal therapy of patients with WHIM has not been 
clearly defined and patients continue to develop infections despite combination therapy with 
G-CSF and IVIG. None of the patients reported before has received hematopoietic stem cell 
transplantation (HSCT). We describe here a successful allogeneic HSCT in a girl with WHIM 
syndrome caused by c.1013G>C sequence variant in the CXCR4 gene.  
Clinical and genetic details of this girl were described in the Journal before (2). IVIG 
infusions and varying doses of G-CSF were started at 6 and half years of age (2). She showed 
clinical improvement in the beginning but continued to develop respiratory infections leading 
to chronic obstructive pulmonary disease afterwards. At age 8 she was treated for a prolonged 
episode of dental periostitis complicated with purulent lymphadenitis. We counseled the 
family on the possibility of HSCT and umbilical cord blood (UCB) transplantation and the 
mother decided to become pregnant. She presented with a new pregnancy and at 11 weeks of 
gestation prenatal genetic testing revealed wild type CXCR4 sequences and HLA genotyping 
showed matching between the patient and the fetus (Fig. 1). Informed consent was obtained 
from the parents and the UCB transplantation was approved by the Hungarian National 
Transplant Committee. Umbilical cord blood stem cells were collected by standard methods 
(7). Pretransplant conditioning regimen consisted of intravenous busulphan and 
cyclophosphamide, followed by a course of rabbit anti-thymocyte globulin. An UCB graft 
containing 1.2x105 CD34+ cells/kg and 3.8x107 nucleated cells/kg was infused without any 
adverse effects. Graft versus host disease (GvHD) prophylaxis consisted of methyl-
prednisolone and cyclosporin A. A flare up of chronic obstructive bronchitis was observed, 
and on day +49 she developed pneumonia caused by Str. pneumoniae. Meropenem therapy 
and bronchodilatator drugs resolved this lung infection. No signs or symptoms of acute or 
chronic GvHD were observed. An absolute neutrophil count of >500/mm3 was achieved on 
post-transplant day 32, and platelet transfusion independence was achieved on day 48. 
Reconstitution of the humoral immune system was also robust with normal-for-age serum 
IgG, IgM, and IgA levels by 100 days after HSCT.
Interphase chromosome analysis and serial variable number of tetra- and 
pentanucleotid repeats examinations were used to confirm donor cell engraftment. The first 
chimerism studies at day +55 post-transplant revealed 12% persisting recipient cells, but 
subsequent serial chimeric analyses demonstrated almost full donor chimerism with less than 
5% recipient cells. During follow-up the patient’s peripheral blood counts and serum 
immunoglobulin concentrations have normalized without any cytokine or IVIG support. One 
year after transplant the patient has near normal hematologic and immunologic parameters. 
She attends school and takes no medication, and is free of infections or post-transplant 
complications. Importantly, chronic lung disease was resolved and she is not taking 
bronchodilator agents. 
In children with WHIM syndrome the diagnosis and supportive treatment with IVIG 
and/or G-CSF may be delayed and severe morbidity or premature death among young 
individuals have been reported. Fatal outcomes due to septicaemia and fulminant Epstein-Barr 
virus positive intestinal B cell lymphoma have been described (8). Furthermore warts are 
generally therapy-resistant requiring repeated laser ablation for management. In addition, the 
long-term use of supportive therapy can cause significant lifestyle restrictions and poor 
quality of life and entails significant costs for health care budget as well. Thus, there is a 
rationale for allogeneic hematopoietic stem cell transplantation as a curative treatment option 
in patients with WHIM syndrome. 
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Figure 1. (A) Clinical phenotype of the patient with WHIM syndrome and her relatives. 
Half-filled circle, the female patient with WHIM; interrupted square, male fetus. (B) 
Automated sequencing profile of genomic DNA showing heterozygous c.1013C>G mutation 
in exon 2 of the CXCR4 gene int he patient and wild type sequences in her parents and the 
male fetus. Mutation position is encircled. In hemizygous patients the c.1013C>G sequence 
variant is predicted to result in p.S338X truncation mutation of the chemokine receptor 
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